DYNT $1.25..Reminder: 1Q 2007 earnings next week.
Next week's 1Q 2007 numbers will be stronger than most recent quarters, and the start of a series of even stronger quarters. Company expects at least 10% revenue growth for 2007 compared to 2006. Net income will likely be about 15c/share in 2007
For 1Q 2007, I expect over $5M in revenues and about 4c/share net income. Compare that with $4.3M reported in 1Q 2006 and a rare (although small $22K) loss.
DYNT HIGHLIGHTS:
* DYNT IS THE LEADER IN LIGHT THERAPY FOR PAIN MANAGEMENT
* FDA APPROVED and PATENTED PRODUCTS
* PROFITABLE AND TRADING AT 0.5 P/S
* STRONG BALANCE SHEET
* STOCK BUYBACK IS ONGOING.
DYNT is one of the safest stock you will find under $2. The company believes the stock is too undervalued and they have a stock buyback that they activate when the stock reaches under $1.3. They do that to prevent manipulation and to get too close to $1. They bought over 50,000 shares this year and have money approved for about 250,000 more shares
Now this company is ready to turn the corner. They predicted at least 10% revenue increase for 2007 compared to 2006. 2006 was a year of transition and they invested a record $1.7M in R&D. This led to the recent release of many new products....the highest number of new products in company history.
In addition to a healthy revenue growth, DYNT is likely to produce a net income of about 15c/share in 2007. This is because the margins for the new products will be higher and the company will reduce R&D expenses by about 5c/share.
SELECTED COMPANY COMMENTS FROM 2006 EARNINGS RELEASE and CC
..."New products introduced during the past year include the Dynatron 702, a stand-alone light therapy device, as well as the new DX9 combination traction and light therapy system. The DX9 system combines the benefits of infrared light therapy using the Dynatron 702 with decompression therapy using the Company's TX900 Traction device. This unique combination of modalities has been reported to be highly effective in the treatment of back pain..."
"Dynatronics also introduced the Dynatron Xp light pad in 2006. This popular product is capable of treating a much larger area than can be treated by other devices. It is 14 times more powerful than light probes currently on the market and makes unattended patient therapy possible..."
"Looking ahead to fiscal 2007, we are pleased to have begun the year with the July 2006 introduction of the new Dynatron X3 infrared light therapy device," said Larry K. Beardall, executive vice president for sales and marketing. "In addition, we plan to introduce the much anticipated DX2 proprietary traction device soon. The DX2 incorporates patent-pending technology and will utilize the new T4 treatment table which is specially designed for traction and decompression therapies. The T4 treatment table is scheduled for introduction in November 2006."
The new DX2 is currently undergoing clinical beta testing and has been previewed at several national trade shows. "Interest in the DX2 from practitioners at the national trade shows has been substantial," reported Beardall. "While the development effort has taken longer than anticipated, we believe this innovative approach to treating back pain will prove to be a great benefit to patients."
ABOUT DYNT:
DYNT is the leader in the area of light therapy for pain management. DYNT's Light therapy products are FDA-approved.
Light Therapy (replaces VIOXX, Celebrex, etc) is non-invasive and has no side effects. It has been used extensively throughout the world for more than twenty years.
Remember when Terrell Owens got injured before the Superbowl a few years ago and it appear that he was going to miss the playoffs?...they used DYNT's light probes to enable this azzhole to get well quickly and shine big time in the Superbowl. At the time it was dubbed a miracle cure...the stock went to $3 in a hurry.....................
AI
